BR112018071950A2 - forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, processo para a produção de uma forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, e composição farmacêutica - Google Patents
forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, processo para a produção de uma forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, e composição farmacêuticaInfo
- Publication number
- BR112018071950A2 BR112018071950A2 BR112018071950A BR112018071950A BR112018071950A2 BR 112018071950 A2 BR112018071950 A2 BR 112018071950A2 BR 112018071950 A BR112018071950 A BR 112018071950A BR 112018071950 A BR112018071950 A BR 112018071950A BR 112018071950 A2 BR112018071950 A2 BR 112018071950A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxy
- polymorphic form
- crystalline polymorphic
- osaterone acetate
- acetate crystalline
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
é fornecida uma forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona com uma comprovada estabilidade (estabilidade de armazenamento, estabilidade de pulverização e características de absorção). num espectro de difração de raios-x de pó, os picos de difração característicos da forma polimórfica cristalina a do acetato de 15¿-hidróxi-osaterona aparecem nos ângulos de difração 2¿ de 9,6° ± 0,2°, 17,1° ± 0,2° e 20,2° ± 0,2°. a forma polimórfica cristalina a tem um ponto de fusão de 280 a 283 °c e é um cristal prismático.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016095382 | 2016-05-11 | ||
| PCT/JP2017/017619 WO2017195804A1 (ja) | 2016-05-11 | 2017-05-10 | １５β－ヒドロキシ－酢酸オサテロンの結晶多形 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071950A2 true BR112018071950A2 (pt) | 2019-02-05 |
Family
ID=60267316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071950A BR112018071950A2 (pt) | 2016-05-11 | 2017-05-10 | forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, processo para a produção de uma forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, e composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10508130B2 (pt) |
| EP (1) | EP3456729B1 (pt) |
| JP (2) | JP7210278B2 (pt) |
| KR (1) | KR102383617B1 (pt) |
| CN (1) | CN109153701B (pt) |
| AU (1) | AU2017264187B2 (pt) |
| BR (1) | BR112018071950A2 (pt) |
| CA (1) | CA3021179A1 (pt) |
| EA (1) | EA034965B1 (pt) |
| ES (1) | ES2829578T3 (pt) |
| MX (1) | MX2018013786A (pt) |
| MY (1) | MY195203A (pt) |
| PH (1) | PH12018502365A1 (pt) |
| SG (1) | SG11201809127PA (pt) |
| WO (1) | WO2017195804A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY195203A (en) * | 2016-05-11 | 2023-01-11 | Aska Pharm Co Ltd | Crystalline Polymorph Of 15B-Hydroxy-Osaterone Acetate |
| CN114502239A (zh) * | 2019-10-02 | 2022-05-13 | Aska制药株式会社 | 排尿障碍改善剂 |
| US20240041899A1 (en) * | 2020-12-18 | 2024-02-08 | Aska Pharmaceutical Co., Ltd. | Solid preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4785103A (en) | 1985-03-07 | 1988-11-15 | Teikoku Hormone Mfg. Co., Ltd. | 2-oxa- or -aza-pregnane compounds |
| JPS61204199A (ja) | 1985-03-07 | 1986-09-10 | Teikoku Hormone Mfg Co Ltd | ２−アザプレグナン化合物 |
| JPS61204198A (ja) | 1985-03-07 | 1986-09-10 | Teikoku Hormone Mfg Co Ltd | ２−オキサプレグナン化合物 |
| JPS62195398A (ja) | 1986-02-21 | 1987-08-28 | Teikoku Hormone Mfg Co Ltd | 黄体ホルモン剤 |
| JP2591640B2 (ja) * | 1988-02-04 | 1997-03-19 | 帝国臓器製薬株式会社 | 新規な２−オキサプレグナン化合物 |
| JP2980992B2 (ja) | 1990-12-28 | 1999-11-22 | 帝国臓器製薬株式会社 | ６−ハロゲノ−２−オキサプレグナ−４，６−ジエン−３−オン化合物の製造方法 |
| JP2591640Y2 (ja) | 1993-05-13 | 1999-03-10 | 株式会社吉野工業所 | 液体収納袋 |
| US8473844B2 (en) | 2004-03-26 | 2013-06-25 | Harman International Industries, Incorporated | Audio related system link management |
| JP6192228B2 (ja) | 2014-05-23 | 2017-09-06 | 本田技研工業株式会社 | 物体認識装置 |
| MY195203A (en) | 2016-05-11 | 2023-01-11 | Aska Pharm Co Ltd | Crystalline Polymorph Of 15B-Hydroxy-Osaterone Acetate |
-
2017
- 2017-05-10 MY MYPI2018001883A patent/MY195203A/en unknown
- 2017-05-10 WO PCT/JP2017/017619 patent/WO2017195804A1/ja unknown
- 2017-05-10 CN CN201780028401.XA patent/CN109153701B/zh active Active
- 2017-05-10 KR KR1020187035313A patent/KR102383617B1/ko active IP Right Grant
- 2017-05-10 US US16/095,782 patent/US10508130B2/en active Active
- 2017-05-10 ES ES17796164T patent/ES2829578T3/es active Active
- 2017-05-10 BR BR112018071950A patent/BR112018071950A2/pt active Search and Examination
- 2017-05-10 MX MX2018013786A patent/MX2018013786A/es active IP Right Grant
- 2017-05-10 EA EA201892566A patent/EA034965B1/ru not_active IP Right Cessation
- 2017-05-10 CA CA3021179A patent/CA3021179A1/en active Pending
- 2017-05-10 JP JP2018517047A patent/JP7210278B2/ja active Active
- 2017-05-10 EP EP17796164.6A patent/EP3456729B1/en active Active
- 2017-05-10 SG SG11201809127PA patent/SG11201809127PA/en unknown
- 2017-05-10 AU AU2017264187A patent/AU2017264187B2/en active Active
-
2018
- 2018-11-09 PH PH12018502365A patent/PH12018502365A1/en unknown
-
2021
- 2021-06-04 JP JP2021094176A patent/JP7241807B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201809127PA (en) | 2018-11-29 |
| ES2829578T3 (es) | 2021-06-01 |
| JP2021121645A (ja) | 2021-08-26 |
| KR102383617B1 (ko) | 2022-04-05 |
| EA201892566A1 (ru) | 2019-04-30 |
| CN109153701B (zh) | 2021-02-02 |
| US10508130B2 (en) | 2019-12-17 |
| EP3456729A1 (en) | 2019-03-20 |
| US20190127417A1 (en) | 2019-05-02 |
| JPWO2017195804A1 (ja) | 2019-03-07 |
| MX2018013786A (es) | 2019-03-28 |
| EP3456729A4 (en) | 2019-05-22 |
| AU2017264187B2 (en) | 2021-02-18 |
| KR20190004787A (ko) | 2019-01-14 |
| PH12018502365A1 (en) | 2019-09-09 |
| EP3456729B1 (en) | 2020-09-02 |
| JP7210278B2 (ja) | 2023-01-23 |
| AU2017264187A1 (en) | 2018-11-15 |
| JP7241807B2 (ja) | 2023-03-17 |
| CA3021179A1 (en) | 2017-11-16 |
| EA034965B1 (ru) | 2020-04-13 |
| CN109153701A (zh) | 2019-01-04 |
| WO2017195804A1 (ja) | 2017-11-16 |
| MY195203A (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128483A2 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos | |
| AR122183A2 (es) | Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato | |
| AR077242A1 (es) | Formas cristalinas del 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}n-(metilsulfonil)acetamida, composiciones farmaceuticas que las contienen, metodo para prepararlas y uso de las mismas en el tratamiento de isquemias, insuficiencia coronaria y asma, entre otras enfermedades. | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| IN2014DN09348A (pt) | ||
| WO2016014927A3 (en) | Crystalline form of nicotinamide riboside | |
| BR112018071950A2 (pt) | forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, processo para a produção de uma forma polimórfica cristalina a de acetato de 15¿-hidróxi-osaterona, e composição farmacêutica | |
| BR112017000551A2 (pt) | um método para preparação de materiais cristalinos mesoporosos microporosos envolvendo um agente de modelagem de mesoporo recuperável e reciclável | |
| AR080490A1 (es) | FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA | |
| NI201500096A (es) | Compuesto químicos | |
| CR20150456A (es) | Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen | |
| WO2012103226A3 (en) | Bendamustine formulations | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| BR112015011898A2 (pt) | forma cristalina a da chidamida, método para preparar a forma cristalina a da chidamida, uso da forma cristalina a da chidamida, forma cristalina b da chidamida, método para preparar a forma cristalina b da chidamida, uso da forma cristalina b da chidamida e formulação farmacêutica para o tratamento de doenças relacionadas à diferenciação e proliferação celular | |
| WO2015000431A9 (zh) | 替唑尼特氨基甲酸酯及其在药学中的应用 | |
| WO2012052478A3 (en) | Topical gel composition | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| WO2015002755A3 (en) | Compounds for the treatment of malaria | |
| MX2015016958A (es) | Sintesis de dicarbamatos de isohexida y derivados de estos. | |
| CA3003108A1 (en) | Storage stable composition comprising rifaximin alpha | |
| PH12016500726A1 (en) | Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation | |
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
| AR082435A1 (es) | Valsartan altamente cristalino | |
| WO2015138276A3 (en) | Retinoic acid receptor-related orphan receptor modulators and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15V | Prolongation of time limit allowed |
Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020 E PORTARIA INPI PR NO 166 DE 27/04/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 15/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07J 73/00 , A61K 31/58 , A61P 13/08 , A61P 17/00 , A61P 17/02 , A61P 17/14 , A61P 35/00 Ipc: A61K 31/58 (2006.01), C07J 73/00 (2006.01), A61P 1 |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |